Patent Granted for New Rheumatoid Arthritis Medication Product R

Christine Miller Health Guide
  • ADVR, a bio-pharmaceutical company, recently announced that effective June 27, 2006, the company received US patent approval for treatment of rheumatoid arthritis by administering Product R (AVR118). Product R is a peptide-nucleic acid preparation. It’s combinations of peptides, amino acids, nucleosides, nucleotides and nucleic acid bases modulate the immune system.

    According to the company’s website, the drug “appears to stimulate the pro inflammatory response required to combat viral infections, such as HIV; and to dampen aberrant autoimmune-type inflammatory responses, which often occur in diseases such as rheumatoid arthritis.” ADVR believes that in the future, Product R may be used to treat a variety of diseases including several conditions associated with cancer; cachexia, or body wasting, in patients with acquired immune deficiency syndrome (AIDS); human immunodeficiency virus (HIV), including AIDS as a combination therapy; type 2 diabetes; human papilloma virus (HPV); and rheumatoid arthritis.
    Add This Infographic to Your Website or Blog With This Code:
    In December 2004 ADVR announced that the FDA had granted IND approval for AVR118 by the United States Food and Drug Administration, allowing the company to conduct a Phase II clinical trial in the United States. The study examined the safety, tolerability, and efficacy of Product R in patients with advanced cancer who are suffering from symptoms of progressive disease. In January 2005 the company announced the final results of its Phase I/II clinical trial of Product R in patients with AIDS. The study results showed that the drug demonstrated evidence of unique patient benefits, a favorable safety profile, and no apparent drug-related adverse events. ADVR is currently in clinical trials for treatment of cachexia (body wasting) in patients with AIDS.
Published On: August 16, 2006